What prophylactic regimens are recommended for prevention of sexually transmitted infections, including HIV post‑exposure prophylaxis (PEP), HIV pre‑exposure prophylaxis (PrEP), and bacterial STI chemoprophylaxis after a single unprotected sexual encounter?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

STI Treatment Prophylaxis

For men who have sex with men (MSM) and transgender women with a recent bacterial STI, prescribe doxycycline 200 mg within 72 hours after condomless sex (doxy PEP), not to exceed 200 mg per 24 hours, which reduces combined incidence of syphilis, chlamydia, and gonorrhea by approximately two-thirds. 1

Bacterial STI Prophylaxis (Doxy PEP)

Who Should Receive Doxy PEP

Strongly recommended for:

  • Gay, bisexual, and other MSM and transgender women with at least one bacterial STI (syphilis, chlamydia, or gonorrhea) diagnosed in the past 12 months 1
  • Both HIV-negative individuals (including those on PrEP) and people living with HIV 2

May be considered for:

  • MSM and transgender women without recent STI diagnosis but anticipating high-risk sexual activities 1
  • Cisgender women on a case-by-case basis (pharmacokinetic modeling suggests efficacy for vaginal exposures, though clinical trial data in Kenyan women showed no benefit, likely due to poor adherence) 1, 3

Insufficient evidence for:

  • Cisgender heterosexual men, transgender men, and other queer/nonbinary persons assigned female at birth 1

Dosing and Administration

  • Dose: 200 mg doxycycline (any formulation) taken as soon as possible within 72 hours after oral, vaginal, or anal sex 1
  • Maximum frequency: Not more than 200 mg per 24 hours (no more than daily dosing) 1, 3
  • Prescription quantity: Provide 30 doses (60 tablets/capsules) at a time based on anticipated sexual activity until next follow-up 3, 4

Efficacy Data

The DoxyPEP trial demonstrated substantial reductions in bacterial STIs 2:

  • Overall STI reduction: 66% (relative risk 0.34 in PrEP cohort, 0.38 in HIV-positive cohort)
  • Chlamydia: 88% reduction (RR 0.12 in PrEP cohort)
  • Syphilis: 87% reduction (RR 0.13 in PrEP cohort)
  • Gonorrhea: 55% reduction (RR 0.45 in PrEP cohort)

Patient Counseling Requirements

Benefits and harms discussion must include:

  • Known side effects: photosensitivity, esophagitis/esophageal discomfort, GI intolerance (nausea, vomiting, diarrhea) 1
  • Potential for antimicrobial resistance development in other pathogens and commensal organisms 1
  • Unknown long-term effects on microbiome 1

Mitigation strategies:

  • Take on a full stomach with a full glass of liquid 1
  • Avoid lying down for 1 hour after taking to prevent esophagitis 1
  • Separate dose by at least 2 hours from dairy products, antacids, and supplements containing calcium, iron, magnesium, or sodium bicarbonate 1
  • No clinically relevant interactions with gender-affirming hormonal therapy 1

Monitoring Schedule

At initiation:

  • Screen for gonorrhea and chlamydia at all anatomic sites of exposure (pharyngeal, rectal, urogenital) 1
  • Serologic testing for syphilis 1
  • HIV testing per CDC guidelines 1

At follow-up (every 3-6 months):

  • Quarterly STI screening at contact sites and blood syphilis testing 3
  • Gonorrhea and chlamydia testing at anatomic sites of exposure 1
  • HIV screening for HIV-negative individuals 1
  • Assess for doxycycline side effects 1
  • Re-assess continued need for doxy PEP 1

HIV Pre-Exposure Prophylaxis (PrEP)

PrEP should be discussed and offered to all sexually active persons without requiring specific risk criteria screening tools. 3

Priority Populations for PrEP Discussion

  • MSM, transgender persons, and nonbinary persons who have sex with cisgender men 3
  • Young adults and adolescents (up to age 24 years) 3
  • Anyone with an STI acquired in the past year 3
  • Persons who inject drugs or use substances (alcohol, stimulants, opioids) 3
  • Sexual partners of persons from regions with high HIV incidence 3
  • Individuals reporting transactional sex 3
  • Incarcerated persons and their partners 3

Rapid PrEP Initiation

  • If HIV test results from within past 7 days are negative, initiate PrEP while awaiting further diagnostics 3
  • If no recent HIV test available, conduct testing and initiate PrEP once results are negative 3

Laboratory Testing for PrEP

At initiation or after long hiatus:

  • HIV RNA test AND laboratory-based antigen-antibody test 3
  • If RNA testing unavailable, may initiate after rapid HIV antibody test while awaiting laboratory-based antigen/antibody result 3

Follow-up monitoring:

  • For long-acting cabotegravir PrEP: rapid HIV antibody test and laboratory-based antigen/antibody test (routine RNA testing not needed) 3
  • For tenofovir-based oral PrEP without RNA testing: repeat antigen/antibody testing 1 month after starting or resuming 3

HIV Post-Exposure Prophylaxis (PEP)

For substantial HIV exposure within 72 hours, initiate a 3-drug PEP regimen immediately. 3

Transition from PEP to PrEP

  • After PEP completion, transition to PrEP if HIV test results remain negative 3
  • This ensures continuous protection for individuals with ongoing risk 3

Comprehensive Sexual Health Approach

Doxy PEP and HIV prophylaxis should be implemented within a comprehensive framework that includes:

  • Risk reduction counseling 1
  • Condom provision and counseling on consistent use 1
  • STI screening and treatment 1
  • Recommended vaccinations 1
  • Linkage to HIV care for persons living with HIV 1
  • Consideration of reducing number of partners 1

Important Caveats

Antimicrobial resistance concerns: Tetracycline-resistant gonorrhea occurred in 5 of 13 participants in doxycycline groups versus 2 of 16 in standard care groups in the DoxyPEP trial 2. Ongoing surveillance is critical, though the substantial reduction in overall STI burden currently outweighs this concern for recommended populations 1.

Adherence is critical: The failed trial in Kenyan cisgender women demonstrated that even with 78% self-reported event-driven dosing coverage, hair studies detected doxycycline in only 29% of participants, highlighting that nonadherence can completely negate efficacy 1.

Serostatus-neutral approach: To reduce stigma, ensure persons diagnosed with HIV are rapidly linked to care while those testing negative are informed about and navigated to PrEP services 3.

Related Questions

In a non‑pregnant adult without severe liver or kidney disease or doxycycline allergy, what is the appropriate doxycycline post‑exposure prophylaxis regimen for bacterial sexually transmitted infections?
What is the role of doxycycline for post‑exposure prophylaxis (PEP) after condomless sexual intercourse?
Which of the listed antibiotics—azithromycin, doxycycline, amoxicillin, or clindamycin—provides the best empiric coverage for a possible sexually transmitted infection exposure?
Can 2 doses of 100mg of doxycycline (doxy) be taken separately on the same day?
Can Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) be used as pre-exposure prophylaxis (PrEP) in sexually active adults at high risk of HIV acquisition with impaired renal function?
What artefacts can occur during arterial blood gas (ABG) sampling and how can they be minimized?
Which medication(s) would you recommend for a patient with bipolar mood swings, irritability, depressive symptoms, and derealization who previously experienced nightmares and excessive sleepiness on lamotrigine?
What is the technique for a continuous locked baseball‑stitch closure of the uterine incision during cesarean delivery?
Can heart failure cause dysphagia in a patient with infective endocarditis?
How should metronidazole (Flagyl) be used to treat trichomoniasis, bacterial vaginosis, and as anaerobic coverage in pelvic inflammatory disease, including dosing and counseling?
Do breast cancer patients taking letrozole require calcium supplementation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.